| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
21,110,000 |
| Market
Cap: |
5.48(M) |
| Last
Volume: |
4,769,812 |
Avg
Vol: |
4,756,501 |
| 52
Week Range: |
$0.2544 - $0.2598 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Plus Therapeutics is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of treatments for patients battling cancer and other life-threatening diseases. The clinical stage drugs in Co.'s pipeline are: Rhenium NanoLiposomes, a radiotherapy for patients with recurrent glioblastoma; DocePLUS™, a chemotherapy for patients with tumors that has been evaluated in a completed U.S. single-center Phase 1 clinical trial; and DoxoPLUS™, a generic chemotherapy that has been evaluated in a completed, bioequivalence clinical trial in the U.S., Canada, and Ukraine versus Janssen's CAELYX® in patients with ovarian cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
24,594 |
55,087 |
105,088 |
| Total Buy Value |
$0 |
$39,199 |
$96,365 |
$125,694 |
| Total People Bought |
0 |
1 |
3 |
5 |
| Total Buy Transactions |
0 |
8 |
12 |
16 |
| Total Shares Sold |
0 |
2,068 |
2,068 |
3,568 |
| Total Sell Value |
$0 |
$4,053 |
$4,053 |
$4,525 |
| Total People Sold |
0 |
1 |
1 |
2 |
| Total Sell Transactions |
0 |
1 |
1 |
2 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hedrick Marc H |
Chief Executive Officer |
• • – |
2021-10-26 |
4 |
B |
$1.66 |
$4,150 |
D/D |
2,500 |
21,080 |
2.73 |
-39% |
|
| Lenk Robert P |
Director |
– • – |
2021-09-13 |
4 |
B |
$1.86 |
$13,011 |
D/D |
7,000 |
10,000 |
2.39 |
-53% |
|
| Sims Andrew John Hugh Macintyre |
Chief Financial Officer |
• – – |
2021-07-28 |
4 |
B |
$1.91 |
$4,286 |
D/D |
2,244 |
4,230 |
2.66 |
-37% |
|
| Sims Andrew John Hugh Macintyre |
Chief Financial Officer |
• – – |
2021-07-27 |
4 |
B |
$2.05 |
$4,071 |
D/D |
1,986 |
1,986 |
2.66 |
-37% |
|
| Hedrick Marc H |
Chief Executive Officer |
• • – |
2021-04-30 |
4 |
B |
$2.28 |
$4,970 |
D/D |
2,183 |
18,580 |
2.73 |
-17% |
|
| Hedrick Marc H |
Chief Executive Officer |
• • – |
2021-03-04 |
4 |
B |
$2.50 |
$6,250 |
D/D |
2,500 |
16,397 |
2.81 |
1% |
|
| Clowes Howard |
Director |
– • – |
2021-03-03 |
4 |
B |
$2.42 |
$7,260 |
D/D |
3,000 |
3,000 |
2.39 |
-6% |
|
| Hedrick Marc H |
Chief Executive Officer |
• • – |
2020-12-10 |
4 |
B |
$1.99 |
$4,975 |
D/D |
2,500 |
13,867 |
2.73 |
6% |
|
| Hedrick Marc H |
Chief Executive Officer |
• – – |
2020-11-30 |
4 |
B |
$2.14 |
$4,708 |
D/D |
2,200 |
11,367 |
2.66 |
- |
|
| Lenk Robert P |
Director |
– • – |
2020-08-25 |
4 |
B |
$2.49 |
$7,465 |
D/D |
3,000 |
3,000 |
2.39 |
-12% |
|
| Petersen Greg |
Director |
– • – |
2020-08-13 |
4 |
B |
$2.80 |
$28,000 |
D/D |
10,000 |
20,000 |
2.39 |
-24% |
|
| Hedrick Marc H |
Chief Executive Officer |
• – – |
2020-08-12 |
4 |
B |
$2.58 |
$10,318 |
D/D |
4,000 |
9,167 |
2.74 |
-16% |
|
| Petersen Greg |
Director |
– • – |
2020-08-12 |
4 |
B |
$2.52 |
$25,200 |
D/D |
10,000 |
10,000 |
2.39 |
-16% |
|
| Hedrick Marc H |
Chief Executive Officer |
• – – |
2020-06-22 |
4 |
B |
$2.10 |
$10,500 |
D/D |
5,000 |
5,167 |
2.74 |
1% |
|
| Postfinance Ag |
10% Owner |
– – • |
2018-02-14 |
4 |
S |
$0.34 |
$161,008 |
D/D |
(473,831) |
4,543,086 |
|
- |
|
| Postfinance Ag |
10% Owner |
– – • |
2018-02-13 |
4 |
S |
$0.31 |
$31,652 |
D/D |
(101,710) |
5,016,917 |
|
- |
|
| Postfinance Ag |
10% Owner |
– – • |
2018-02-12 |
4 |
S |
$0.31 |
$58,324 |
D/D |
(185,272) |
5,118,627 |
|
- |
|
| Postfinance Ag |
10% Owner |
– – • |
2018-02-09 |
4 |
S |
$0.34 |
$2,568 |
D/D |
(7,552) |
5,303,899 |
|
- |
|
| Postfinance Ag |
10% Owner |
– – • |
2018-02-08 |
4 |
S |
$0.34 |
$78,434 |
D/D |
(228,603) |
5,311,451 |
|
- |
|
| Swissquote Bank Sa |
|
• • • |
2018-01-11 |
4 |
S |
$0.34 |
$24,716 |
D/D |
(72,630) |
5,328,229 |
|
- |
|
| Swissquote Bank Sa |
|
• • • |
2018-01-10 |
4 |
S |
$0.38 |
$6,007 |
D/D |
(15,796) |
5,400,859 |
|
- |
|
| Swissquote Bank Sa |
|
• • • |
2018-01-09 |
4 |
S |
$0.37 |
$38,332 |
D/D |
(100,000) |
5,416,655 |
|
- |
|
| Harris John David |
VP and GM Cell Therapy |
• – – |
2016-08-10 |
4 |
B |
$2.03 |
$5,075 |
D/D |
2,500 |
7,000 |
2.74 |
- |
|
| Lyons Gary A |
Director |
– • – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
1,900 |
4,358 |
|
- |
|
| Rickey David |
Director |
– • – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
22,000 |
71,226 |
|
- |
|
102 Records found
|
|
Page 2 of 5 |
|
|
